Dr Honorine Lebraud
Chemistry, Astex Pharmaceuticals
Chemistry, Astex Pharmaceuticals
Lebraud., et al., Quantitation of ERK1/2 inhibitor cellular target occupancies with a reversible slow off-rate probe. Chem. Sci. October 2018, Issue 37; Doi.org/10.1039/c8sc02754d
Lebraud, H. and Heightman, T. D. Protein degradation: a validated therapeutic strategy with exciting prospects. Essays in Biochemistry. 2017 Nov8;61(5):517-527. Doi: 10.1042/EBC20170030.
Sipthorp, J.; Lebraud, H.; Gilley, R.; Kidger, A. M.; Okkenhaug, H.; Saba-El-Leil, M.; Meloche, S.; Caunt, C. J.; Cook, S.; Heightman, T. D. Visualization of Endogenous ERK1/2 in Cells with a Bioorthogonal Covalent Probe. Bioconjugate Chemistry (2017) DOI 10.1021/acs.bioconjchem.7b00152.
Lebraud, H.; Wright, D. J.; Johnson, C. N.; Heightman, T. D. Protein degradation by in-cell self-assembly of PROTACs. ACS Central Science, 2016; DOI 10.1021/acscentsci.6b00280
Lebraud, H.; Wright, D. J.; East, C. E.; Holding, F. P.; O’Reilly, M.; Heightman, T. D. In-gel activity-based protein profiling of a clickable covalent ERK1/2 inhibitor. Molecular BioSystems, 2016; 10.1039/c6mb00367b.
2017 Chemical Biology Poster Prize – Poster prize sponsored by RSC and won at the Chemical Biology Symposium, London.
2016 Vocation for Medicinal Chemistry – Poster prize sponsored by the Laboratoires Servier and won at the 52nd International Conference on Medicinal Chemistry, Caen.